EGCG Regulates Cell Apoptosis of Human Umbilical Vein Endothelial Cells Grown on 3I6L Stainless Steel for Stent Implantation

• Published in: Drug design, development and therapy Vol. 15; p. 493
• Main Authors: Wang, Jinpeng, Wang, Yue, Zhao, Yuyi, Zhao, Jinbin, Zhang, Beilin, Xu, Kun
• Format: Journal Article
• Language: English
• Published: Dove Medical Press Limited 28.02.2021
• Subjects: Apoptosis; Blood clot; Catechin; Coatings; Endothelium; Steel, Stainless; Stent (Surgery); Thrombosis; China
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S296548

Background: Nowadays, medical grade 316L stainless steel (316L SS) is being widely used for intravascular stents, and the drug-eluting stent (DES) system is able to significantly reduce the occurrences of in-stent restenosis. But the drugs and the polymer coating used in DES potentially induce the forming of late stent thrombosis. In order to reduce the occurrence of ISR after stent implantation, the development of novel drugs for DESs is urgently needed. Methods: This study aimed to investigate the potential mechanisms of epigallocatechin-3-gallate (EGCG) on human umbilical vein endothelial cells (HUVEC) grown on 316L stainless steel (316L SS) using flow cytometry and Q-PCR methods. Results: Our results showed that EGCG (12.5, 25, 50, 100 [micro]mol/L) significantly inhibited HUVEC proliferation. Flow cytometry analysis indicated that EGCG (25, 50, 100 [micro]mol/L) induced apoptosis. Moreover, qRT-PCRrevealed that genes associated with cell apoptosis (caspase-3, 8, 9, Fas) and autophagy (Atg 5, Atg 7, Atg 12) were up-regulated after EGCG treatment. Conclusion: These findings indicate that EGCG possesses chemo preventive potential in stent coating which may serve as a novel new drug for stent implantation. Keywords: EGCG, 316 stainless steel, HUVECs, apoptosis